• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $APRE

    Aprea Therapeutics Inc.

    Subscribe to $APRE
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.

    IPO Year: 2019

    Exchange: NASDAQ

    Website: aprea.com

    Peers

    $BEAM

    Recent Analyst Ratings for Aprea Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    8/20/2021Neutral → Underweight
    JP Morgan
    8/16/2021Buy → Hold
    Berenberg
    8/16/2021$6.00 → $4.00Neutral
    HC Wainwright & Co.
    8/13/2021$6.00 → $5.00Sector Perform
    RBC Capital
    8/13/2021$5.00 → $3.00Equal-Weight → Underweight
    Morgan Stanley
    See more ratings

    Aprea Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

      Two programs with clinical data readouts in 2H/2025 Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing with preliminary clinical data expected in 2H/2025; Trial now open for enrollment to patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) Preliminary data for ongoing ADI-270 Phase 1 clinical trial in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) expected in 2H/2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended M

      5/6/25 4:01:00 PM ET
      $ACET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio Appoints Michael Grissinger to the Board of Directors

      --Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions-- Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. "We are honored to welcome Michael to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "His extensive

      4/17/25 7:00:00 AM ET
      $ACET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

      DOYLESTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that a patient with HPV+ head and neck squamous cell carcinoma (HNSCC) has been dosed in the ongoing ACESOT-1051 clinical trial evaluating APR-1051. This is the first patient to be dosed in Cohort 5 (70 mg once daily) of the study. Open label data from the study are expected in the second half of 2025. WEE1 inhibition has emerged as a promising strategy for targeting tumor cells with high r

      3/31/25 8:30:00 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

      ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected to maximize clinical benefit of ATR inhibitor ATRN-119; plan to complete dose escalation H2 2025 $22.8 million in cash and cash equivalents as of December 31, 2024 DOYLESTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today reported financial

      3/25/25 8:30:00 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

      DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, announced today that it has entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center. Under the agreement, Aprea will supply its proprietary WEE1 kinase inhibitor, APR-1051, to support preclinical research aimed at exploring its potential in treating HPV+ and HPV- head and neck squamous cell carcinoma (HNSCC) expressing genomic markers of replication stress. The agreement will enable

      3/11/25 8:30:00 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

      DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on its existing patent portfolio. "Our strong patent portfolio reflects our commitment to innovation and leadership in the field of DNA Damage Response therapeutics," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "Intellectual property is an essential component of Aprea's strategy, enabling us to advance first in class and best in class oncology treatments

      2/5/25 8:00:00 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

      Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's experimental drug, ATRN-119, over a 24-hour daily cycle New regimen potentially optimizes clinical outcomes and strengthens the clinical path forward ATRN-119 is the first macrocyclic ATR inhibitor to enter clinical trials DOYLESTOWN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision oncology company developing innovative therapies for cancers with specific genetic alterations to potentially minimize damage to healthy cells, announced today that the first patient has been dosed at Dos

      12/11/24 8:30:00 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

      Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected toxicities Philippe Pultar, MD engaged as senior medical advisor to support the development and advancement of APR-1051 $26.2 million in cash and cash equivalents as of September 30, 2024 with cash runway for at least twelve months DOYLESTOWN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the third quarter ended September 30, 2024, and provided a bu

      11/7/24 8:00:00 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

      Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need; active enrollment is ongoing at three sites in the U.S. Preliminary results to date demonstrate APR-1051 is safe and well-tolerated with no hematologic toxicity DOYLESTOWN, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that preliminary safety results on its WEE1 inhibitor APR-1051 are highlighted in a poster being presented today at the EORTC-NCI-AACR Symposium on Molecular Targets

      10/23/24 8:30:00 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

      DOYLESTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad, President and CEO, will participate in two presentations at the Maxim Healthcare Virtual Summit, to take place October 15 to 17, 2024. Presentation Details Session:Precision and Immune Oncology PanelDate/ time:Wednesday, October 16, 2:00 - 3:00 PM ET  Session:Fireside ChatDate/ time:Thursday, October 17, 3:30 - 4:00 PM ET This conference will be hosted live on M-Vest. To access the above presentations, sign up to become an M-Ve

      10/14/24 8:30:00 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aprea Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations

      BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and six months ended June 30, 2022 and provided a business update. "This is an exciting time for Aprea as we advance our ATR program into clinical development this year, continue to progress our WEE1 program toward IND submission and leverage our unique discovery platform capabilities to build for future success," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "We believe o

      8/11/22 4:15:00 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

      BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. ("Atrin") and reported financial results for the three months ended March 31, 2022. Business Operations Update:  On May 16, 2022 Aprea completed the acquisition of Atrin, a privately held biotechnology company focused on the discovery and development of novel therapeutics targeting proteins in the DNA damage response, or DDR, pathway in oncology through synthetic lethality. The Company believes its cash and cash

      5/16/22 9:21:33 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

      BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its clinical trials of eprenetapopt in combination with azacitidine in its myeloid malignancy programs. The partial clinical hold does not apply to the Company's ongoing clinical trials in lymphoid malignancies and solid tumors, or the APR-548 clinical trial. There are approximately 20 patients currently receiving eprenetapopt in combination with azacitidine i

      8/5/21 5:00:00 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aprea Therapeutics Inc. SEC Filings

    See more
    • SEC Form DEFA14A filed by Aprea Therapeutics Inc.

      DEFA14A - Aprea Therapeutics, Inc. (0001781983) (Filer)

      4/22/25 4:15:12 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Aprea Therapeutics Inc.

      DEF 14A - Aprea Therapeutics, Inc. (0001781983) (Filer)

      4/22/25 4:05:14 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Aprea Therapeutics Inc.

      SCHEDULE 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

      4/8/25 3:14:41 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Aprea Therapeutics Inc.

      10-K - Aprea Therapeutics, Inc. (0001781983) (Filer)

      3/25/25 8:45:37 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)

      3/25/25 8:40:16 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Aprea Therapeutics Inc.

      SCHEDULE 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

      2/13/25 12:15:12 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Aprea Therapeutics Inc.

      SCHEDULE 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

      2/10/25 12:56:26 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Aprea Therapeutics Inc.

      SCHEDULE 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

      2/10/25 8:36:31 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)

      2/5/25 8:30:18 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)

      1/13/25 8:00:39 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aprea Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President/CEO Gilad Oren bought $10,110 worth of shares (5,500 units at $1.84), increasing direct ownership by 2% to 345,620 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      4/4/25 7:30:11 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President/CEO Gilad Oren bought $1,958 worth of shares (500 units at $3.92), increasing direct ownership by 0.15% to 333,395 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/24/24 8:30:13 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Duey Marc bought $131,700 worth of shares (30,000 units at $4.39), increasing direct ownership by 14% to 240,113 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/17/24 8:30:55 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President/CEO Gilad Oren bought $725 worth of shares (250 units at $2.90), increasing direct ownership by 0.08% to 332,895 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/16/24 8:31:25 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Duey Marc bought $490 worth of shares (190 units at $2.58), increasing direct ownership by 0.09% to 210,113 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/16/24 8:30:47 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. bought $123 worth of shares (50 units at $2.46), increasing direct ownership by 0.26% to 19,368 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/16/24 8:30:13 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Seizinger Bernd R. bought $26,800 worth of shares (10,000 units at $2.68), increasing direct ownership by 29% to 44,730 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/15/24 8:31:44 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President/CEO Gilad Oren bought $2,971 worth of shares (1,150 units at $2.58), increasing direct ownership by 0.35% to 332,645 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/15/24 8:31:01 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. bought $1,174 worth of shares (450 units at $2.61), increasing direct ownership by 2% to 19,318 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/15/24 8:30:16 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hamill John P. bought $7,363 worth of shares (1,010 units at $7.29), increasing direct ownership by 7% to 15,503 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      3/14/24 8:54:37 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aprea Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    Aprea Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • President/CEO Gilad Oren bought $10,110 worth of shares (5,500 units at $1.84), increasing direct ownership by 2% to 345,620 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      4/4/25 7:30:11 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. was granted 3,365 shares, increasing direct ownership by 17% to 22,733 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      3/31/25 4:31:29 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President/CEO Gilad Oren was granted 6,725 shares, increasing direct ownership by 2% to 340,120 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      3/31/25 4:30:32 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Duey Marc sold $29,583 worth of shares (6,462 units at $4.58), decreasing direct ownership by 3% to 233,651 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/25/24 5:42:04 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President/CEO Gilad Oren bought $1,958 worth of shares (500 units at $3.92), increasing direct ownership by 0.15% to 333,395 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/24/24 8:30:13 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Duey Marc bought $131,700 worth of shares (30,000 units at $4.39), increasing direct ownership by 14% to 240,113 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/17/24 8:30:55 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President/CEO Gilad Oren bought $725 worth of shares (250 units at $2.90), increasing direct ownership by 0.08% to 332,895 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/16/24 8:31:25 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Duey Marc bought $490 worth of shares (190 units at $2.58), increasing direct ownership by 0.09% to 210,113 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/16/24 8:30:47 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. bought $123 worth of shares (50 units at $2.46), increasing direct ownership by 0.26% to 19,368 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/16/24 8:30:13 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Seizinger Bernd R. bought $26,800 worth of shares (10,000 units at $2.68), increasing direct ownership by 29% to 44,730 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/15/24 8:31:44 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio Appoints Michael Grissinger to the Board of Directors

      --Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions-- Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. "We are honored to welcome Michael to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "His extensive

      4/17/25 7:00:00 AM ET
      $ACET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

      DOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has engaged Philippe Pultar, MD as its senior medical advisor to support Aprea with developing and advancing APR-1051, Aprea's potential best in class WEE1 inhibitor. Dr. Pultar is a seasoned pharmaceutical executive with extensive experience in oncology, including the development of a WEE1 inhibitor (azenosertib) from early to late-stage clinical development. Dr. Pultar has vast experience in clinical development within both large and early-stag

      10/9/24 8:30:00 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

      Brings proven leadership and successful track record to Halda as the company enters the next stage of growth as clinical-stage company Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced that it has appointed Christian Schade as President and Chief Executive Officer and a member of the Board of Directors. Chris brings more than 20 years of public and private pharmaceutical and biotechnology industry experience, including building, financing and leading biotechnology companies through the clinical stages of pipeline development and formation of value-creating de

      10/1/24 8:30:00 AM ET
      $APRE
      $IART
      $OMGA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      DOYLESTOWN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced the appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer (CMO) of the Company, effective May 1, 2024. Dr. Mirza has been an integral part of the Company's senior team as a consultant since February, 2023 and will now assume a more central role in leading the Company's development of its expanding clinical pipeline. "Aprea is at a critical point of enriching and expanding its clinical programs. Dr. Mirza has already made significant contribu

      5/2/24 9:15:00 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman

      DOYLESTOWN, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it has appointed Dr. Jean-Pierre Bizzari to its Board of Directors and is naming Dr. Richard Peters as its new Chairman of the Board. Dr. Bizzari will replace Mr. Christian Schade, who is stepping down from the Board. "We warmly welcome Dr. Jean-Pierre Bizzari to our Board of Directors. Jean-Pierre is an esteemed industry thought leader and was the Group Head Clinical Development Oncology at Celgene where he was responsible for developing some of the most

      8/24/23 7:30:00 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors

      DOYLESTOWN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointment of Gabriela Gruia, M.D. to its Board of Directors, effective as of May 5, 2023. Dr. Gruia joins Aprea with over 25 years of clinical, regulatory and life science leadership experience. "We are honored to welcome Dr. Gruia to the Aprea Board of Directors, where her deep experience and accomplishments in drug development and regulatory affairs will be of immense importance in advanci

      5/8/23 8:00:00 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aprea Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Aprea Therapeutics Inc.

      SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)

      10/10/24 4:07:13 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aprea Therapeutics Inc.

      SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)

      2/14/24 8:00:11 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aprea Therapeutics Inc. (Amendment)

      SC 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

      2/7/24 6:55:18 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aprea Therapeutics Inc.

      SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)

      3/3/23 6:03:56 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aprea Therapeutics Inc. (Amendment)

      SC 13D/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

      11/15/22 5:08:05 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aprea Therapeutics Inc. (Amendment)

      SC 13D/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

      6/30/22 4:34:53 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aprea Therapeutics Inc. (Amendment)

      SC 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

      2/10/22 8:44:54 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aprea Therapeutics, Inc. (Amendment)

      SC 13D/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

      10/15/21 4:50:03 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aprea Therapeutics, Inc. (Amendment)

      SC 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

      10/12/21 4:18:54 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aprea Therapeutics, Inc.

      SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)

      3/24/21 5:13:51 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aprea Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aprea Therapeutics downgraded by JP Morgan

      JP Morgan downgraded Aprea Therapeutics from Neutral to Underweight

      8/20/21 5:10:20 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics downgraded by Berenberg

      Berenberg downgraded Aprea Therapeutics from Buy to Hold

      8/16/21 7:29:48 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Aprea Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Aprea Therapeutics with a rating of Neutral and set a new price target of $4.00 from $6.00 previously

      8/16/21 6:35:21 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on Aprea Therapeutics with a new price target

      RBC Capital reiterated coverage of Aprea Therapeutics with a rating of Sector Perform and set a new price target of $5.00 from $6.00 previously

      8/13/21 9:54:49 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Aprea Therapeutics from Equal-Weight to Underweight and set a new price target of $3.00 from $5.00 previously

      8/13/21 5:08:47 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on Aprea Therapeutics with a new price target

      RBC Capital reiterated coverage of Aprea Therapeutics with a rating of Sector Perform and set a new price target of $8.00 from $10.00 previously

      3/17/21 7:48:37 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care